Discussions regarding late-breaking cardiovascular clinical trials among leading medical scientists are placing considerable emphasis on individualized patient care, particularly in the area of dual antiplatelet therapy, according to an analyst with research and consulting firm GlobalData.

A study that identifies new heart attack risk factors and supports the use of a blood test for detection in patients will be published in the AACE (American Association of Clinical Endocrinologists) Journal.

InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major cardiology congress in Israel in December. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next-generation MGuard drug eluting stent (DES) platform. The company also announced ipsilateral diffusion weighted magnetic resonance imaging (DW-MRI) results from the CARENET Trial for the CGuard system which successfully completed enrollment in July.

The issue of sudden cardiac death has long been a concern of heart specialists, for cardiac arrest often hits young, apparently healthy and athletic people out of the blue.

Patients who were obese before developing heart failure lived longer than normal weight patients with the same condition according to a new study in the Journal of the American College of Cardiology that examined the “obesity paradox” by following obese and non-obese heart failure patients for more than a decade.

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold.

Innovative Cardiovascular Solutions LLC has completed a Class A Unit financing totaling $5 million to fund its Emblok Embolic Protection Catheter.